PATENT CLAIM ANALYSIS

Application Number: 15991705
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["548", "356100"]

Abstract:
The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.

Claim (Index 20):
The method of  claim 1 , wherein the compound is Example 1 or a pharmaceutically acceptable salt thereof, wherein the stereomeric purity is at least 90%.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 93.0
- Lexical Diversity: 1.22857
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14844297', '15377662', '14191922', '13950195', '13300351']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7832307452523052
- 35 USC 102 Novelty (BERT): 0.5876277383159767
- Combined Prediction Score: 0.7636704445586724
- Mean Citation Score: 450.07634400000006
- Max Citation Score: 499.13226
- Similarity Product: 424.5702028681362

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test